Lexicon Pharmaceuticals Inc (STU:LX31)
€ 4.096 0 (0%) Market Cap: 275.49 Mil Enterprise Value: 126.67 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 52/100

Lexicon Pharmaceuticals Inc at Jefferies Healthcare Conference (Virtual) Transcript

Jun 02, 2020 / 06:00PM GMT
Release Date Price: €1.77 (+2.69%)
Unidentified Participant

It is my pleasure to introduce Lonnel Coats, President and Chief Executive Officer at Lexicon Pharmaceuticals, to present at the Jefferies Virtual Healthcare Conference.

Lonnel Coats
Lexicon Pharmaceuticals, Inc. - President & CEO

Thank you and thank you all for joining us on this conference. I'm Lonnel Coats, President and Chief Executive Officer of Lexicon Pharmaceuticals. Today I'll be making this presentation on behalf of all the extraordinary men and women here at Lexicon who toils every day to advance our science into the hands of patients. Also today I will be making forward-looking statements, some of these will have risks. All of my risks are covered in our SEC filings.

Let me jump right in. For those who may not be familiar with Lexicon, we have a scientific platform that has produced two approved products in a pipeline of innovative drug candidates. The first approved product is XERMELO, which is proved here in the United States for carcinoid syndrome diarrhea, and we have a partnership outside the US in Japan with Ipsen

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot